Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revacept in stable coronary artery disease patients undergoing elective PCI
2015-000686-32Phase 2Completed
- Sponsor
- Deutsches Herzzentrum München
- Start
- Mar 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of revacept in coronary arteriosclerosis, sponsored by Deutsches Herzzentrum München. Primary endpoint: Primary composite endpoint of death or myocardial injury. Started Mar 2015; status: completed.
02
Drugs
revacept
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2015-000686-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000686-32.